Bevacizumab is a humanized monoclonal antibody directed against VEGF-A, approved in 2004, and used in clinic for treatment of different tumors, such as GBM, colorectal, ovarian and BC (262, 263). This evidence concerns the gene VEGFA and breast cancer.